Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease with a History of Exacerbations - OBERON

Study identifier:D9180C00003

ClinicalTrials.gov identifier:NCT05166889

EudraCT identifier:2021-003797-30

CTIS identifier:N/A

Recruiting

Official Title

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (OBERON)

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 3

Healthy volunteers

No

Study drug

Tozorakimab, Placebo

Sex

All

Estimated Enrollment

1099

Study type

Interventional

Age

40 Years - 130 Years

Date

Study Start Date: 03 Jan 2022
Estimated Primary Completion Date: 05 Feb 2026
Estimated Study Completion Date: 04 May 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria